TREATMENT OF BORRELIA-INFECTION BY MACROL ID-ANTIBIOTICS

Lyme disease definitely constitutes a therapeutic challenge. There has been conflicting evidence as far as the successful use of macrolides in this context is concerned. Acithromycin, however, has been unanimou sly reported as successful in early stages of Lyme disease, whereas le ss convincing evidence has been presented for erythromycin and roxithr omycin. The latter has received some attention when combined with co-t rimoxazole as a strategy in late Lyme disease refractory to convention al therapy. In summary, macrolides are potent anti-Borrelia agents but certainly require further investigation.